🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,013 results for “AB” Clear

  1. Aficamten, Tablet placebo for aficamten 5mg tablet

    Cytokinetics (Ireland) Limited

    SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

    phase 3 small molecule active

    1 trial

  2. Afinitor 10 mg tablets, Aromasin 25 mg coated tablets, Faslodex 250 mg solution for injection., Afinitor 5 mg tablets

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Hormone receptor-positive, her2-negative advanced/metastatic breast cancer

    phase 3 small molecule active

    1 trial

  3. Afinitor 2.5 mg tablets, Afinitor 10 mg tablets

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Children, adolescents and adults with newly diagnosed diffuse intrinsic pontine glioma and other diffuse midline gliomas H3K28M mutant or EZHIP positive

    phase 3 small molecule active

    1 trial

  4. Afinitor 5 mg tablets, PLACEBO

    Cancer Prevention Pharma (Ireland) Limited

    Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free

    phase 3 small molecule active

    1 trial

  5. Albuterol sulfate (ABS)

    Teva Pharma GmbH

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    1 trial

  6. Alecensa 150 mg hard capsules, VINORELBINE, Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin ACTAVIS 10 mg/ml concentrat pentru soluţie perfuzabilă, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Alecensa 150 mg hard capsules

    Roche Registration Limited

    Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  7. Alemtuzumab

    United Therapeutics Europe Ltd

    Kidney Transplantation

    phase 3 small molecule completed

    1 trial

  8. Alirocumab

    Regeneron UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  9. Alirocumab

    Regeneron UK Limited

    Type2 Diabetes

    phase 3 small molecule completed

    1 trial

  10. Alirocumab

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule active

    18 trials

  11. Alirocumab

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    2 trials

  12. Alirocumab

    First Tracks Biotherapeutics

    Intracranial Atherosclerosis

    phase 3 small molecule active

    1 trial

  13. Alirocumab

    Regeneron UK Limited

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule completed

    1 trial

  14. Alirocumab

    Regeneron UK Limited

    Coronary Vessel

    phase 3 small molecule completed

    1 trial

  15. Alirocumab 150 MG/ML [Praluent]

    Regeneron UK Limited

    Hemodialysis

    phase 3 small molecule active

    1 trial

  16. Alirocumab SAR236553

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    1 trial

  17. Alogliptin

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule completed

    9 trials

  18. Alogliptin Benzoate

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  19. Alogliptin and glimepiride

    Takeda Pharmaceuticals International AG

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  20. Alogliptin and glyburide

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  21. Alogliptin and insulin

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  22. Alogliptin and metformin

    Takeda Pharmaceuticals International AG

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  23. Alogliptin and metformin

    Takeda Pharmaceuticals International AG

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  24. Alogliptin and pioglitazone

    Takeda Pharmaceuticals International AG

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources